Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
11.19
+0.47 (4.38%)
Nov 4, 2024, 4:00 PM EST - Market closed

Artiva Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
29.2633.494.932--
Revenue Growth (YoY)
493.31%579.21%146.30%---
Gross Profit
29.2633.494.932--
Selling, General & Admin
13.3913.9120.7812.864.432.09
Research & Development
47.7150.2543.9842.4113.851.32
Operating Expenses
61.164.1664.7655.2718.273.41
Operating Income
-31.84-30.67-59.83-53.27-18.27-3.41
Interest Expense
-----0.2-0.26
Interest & Investment Income
2.332.541.29-00.03
Other Non Operating Income (Expenses)
-2.84-0.41-0.2-18.550.48-0.7
EBT Excluding Unusual Items
-32.35-28.55-58.74-71.83-17.99-4.35
Gain (Loss) on Sale of Investments
-0.1-0.1----
Pretax Income
-32.45-28.65-58.74-71.83-17.99-4.35
Income Tax Expense
0.070.070.05---
Net Income
-32.53-28.72-58.79-71.83-17.99-4.35
Net Income to Common
-32.53-28.72-58.79-71.83-17.99-4.35
Shares Outstanding (Basic)
111111
Shares Outstanding (Diluted)
111111
Shares Change (YoY)
5.55%4.70%11.80%8.60%3.59%-
EPS (Basic)
-40.19-35.78-76.67-104.73-28.49-7.13
EPS (Diluted)
-40.19-35.78-76.67-104.73-28.49-7.13
Free Cash Flow
-51.49-50.69-57.13-17.03-13.83-3.45
Free Cash Flow Per Share
-63.62-63.14-74.51-24.83-21.89-5.65
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-108.84%-91.58%-1213.32%-2660.94%--
Profit Margin
-111.17%-85.75%-1192.21%-3587.66%--
Free Cash Flow Margin
-176.00%-151.34%-1158.55%-850.55%--
EBITDA
-29.5-28.41-58.67-53.02-18.2-3.4
EBITDA Margin
-100.84%-84.81%----
D&A For EBITDA
2.342.271.160.250.070.01
EBIT
-31.84-30.67-59.83-53.27-18.27-3.41
EBIT Margin
-108.84%-91.58%----
Revenue as Reported
29.2633.494.93---
Source: S&P Capital IQ. Standard template. Financial Sources.